Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Drops By 8.6%

AnaptysBio, Inc. (NASDAQ:ANAB) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a decline of 8.6% from the January 15th total of 6,600,000 shares. Based on an average trading volume of 662,000 shares, the days-to-cover ratio is currently 9.1 days. Currently, 23.3% of the shares of the stock are short sold.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $21.22 on Tuesday. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $41.31. The stock has a market capitalization of $645.72 million and a PE ratio of -3.49. The stock has a 50-day simple moving average of $15.75 and a 200 day simple moving average of $25.63.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 65,184 shares of the stock in a transaction dated Monday, December 30th. The shares were acquired at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the acquisition, the director now owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This represents a 0.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. lifted its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in AnaptysBio by 202.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 36,300 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after acquiring an additional 22,164 shares in the last quarter. Victory Capital Management Inc. raised its holdings in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wolfe Research assumed coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a report on Wednesday, February 12th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Guggenheim lowered their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Finally, JPMorgan Chase & Co. reduced their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.